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PXPEDITED REVIEW
utologous Bone Marrow Stem Cell Mobilization
nduced by Granulocyte Colony-Stimulating Factor
fter Subacute ST-Segment Elevation Myocardial
nfarction Undergoing Late Revascularization
inal Results From the G-CSF-STEMI (Granulocyte Colony-Stimulating
actor ST-Segment Elevation Myocardial Infarction) Trial
arkus G. Engelmann, MD,* Hans D. Theiss, MD,* Christine Hennig-Theiss,* Armin Huber, MD,†
ernd J. Wintersperger, MD,† Anja-Eva Werle-Ruedinger,† Stefan O. Schoenberg, MD,†
erhard Steinbeck, MD,* Wolfgang-M. Franz, MD*
unich, Germany
OBJECTIVES The purpose of this investigator-driven, prospective, randomized, double-blinded, placebo-
controlled phase II study was to compare the effects of granulocyte colony-stimulating factor
(G-CSF) on the improvement of myocardial function in patients undergoing delayed percuta-
neous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
BACKGROUND Experimental and early clinical studies suggest that transplantation of stem cells improves
cardiac regeneration and neovascularization after acute myocardial infarction. Most investi-
gators have utilized either a direct injection or intracoronary infusion of bone marrow–derived
cells, but early cytokine-mediated mobilization of stem cells has been reported to show similar
improvement in cardiac function.
METHODS Forty-four patients with late revascularized subacute STEMI were treated either with G-CSF
or placebo over 5 days after successful PCI. Primary end points were change of global and
regional myocardial function from baseline (1 week after PCI) to 3 months after PCI assessed
by magnetic resonance imaging (MRI). Secondary end points consisted of characterization of
mobilized stem cell populations, assessment of safety parameters up to 12 months including
6-month angiography, as well as myocardial perfusion assessed by MRI.
RESULTS Global myocardial function from baseline (1 week after PCI) to 3 months improved in both
groups, but G-CSF was not superior to placebo (ejection fraction 6.2  9.0 vs. 5.3  9.8%, p
 0.77). A slight but non-significant improvement of regional function occurred in both
groups. Granulocyte colony-stimulating factor resulted in mobilization of endothelial
progenitor cell populations and was well tolerated with a similar rate of target lesion
revascularization from in-stent restenosis. In both groups major adverse cardiovascular events
occurred in a comparable frequency. Granulocyte colony-stimulating factor resulted in
significant improvement of myocardial perfusion 1 week and 1 month after PCI.
CONCLUSIONS Granulocyte colony-stimulating factor treatment after PCI in subacute STEMI is feasible
and relatively safe. However, patients do not benefit from G-CSF when PCI is performed
late. Granulocyte colony-stimulating factor results in improved myocardial perfusion of the
infarcted area, which may reflect enhanced neovascularization. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.0441712–21) © 2006 by the American College of Cardiology Foundation
d
t
(
g
c
(
s
t
gate coronary reperfusion is frequently associated with left
entricular remodeling leading to sudden cardiac death or
rogressive heart failure. The outcome of patients suffering
rom subacute myocardial infarction (MI) is considered to be
erious; patients are threatened by progressive myocardial
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ccepted July 3, 2006.ysfunction and increased mortality resulting from the long
ime interval between onset of infarction to revascularization
1). Animal experiments have shown that application of
See page 1722
ranulocyte colony-stimulating factor (G-CSF) after MI
an improve mortality and ameliorate myocardial damage
2). Early non-placebo controlled human trials report
afety of G-CSF administration after immediate percu-
aneous coronary intervention (PCI) and improvement of
lobal left ventricular function (3,4). However, the use of
-CSF was made uncertain by a report of increased rate
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October 17, 2006:1712–21 G-CSF in Myocardial Infarctionf in-stent restenosis (ISR) when G-CSF was adminis-
ered before PCI (5).
The aim of this investigator-driven, prospective, random-
zed, double-blinded clinical study was to investigate safety
nd efficacy of G-CSF in patients undergoing delayed
evascularization after subacute ST-segment elevation myo-
ardial infarction (STEMI).
ATERIALS AND METHODS
tudy protocol. Starting in December 2002, we prospec-
ively enrolled patients suffering from subacute STEMI
ith late revascularization achieved by PCI. Inclusion cri-
eria were subacute STEMI, onset of pain more than 6 h
nd up to 7 days, akinesia of at least 1 myocardial segment
emonstrated by echocardiography at admission, suitable
or PCI of the infarct-related artery, and no contraindica-
ions against electrocardiogram (ECG)-triggered magnetic
esonance imaging (MRI) (Fig. 1). Patients who were
linically unstable, had other severe underlying illnesses, or
ontraindications against G-CSF were excluded. Patients
aving aspirin intolerance or currently receiving steroids,
mmunosuppressants, or cytostatics were also excluded.
one of the patients had a history of MI.
After acute PCI of the infarct-related artery using bare
etal stents, patients were treated with clopidogrel for at
east 4 weeks. Patients were randomized to receive either
-CSF (Filgrastim, Amgen GmbH, Munich, Germany) at
dose of 10 g/kg body weight/day subcutaneously or
lacebo (saline). Randomization and preparation of the
tudy medication using neutral syringes were independently
erformed by the department of pharmacy of our institu-
ion. Follow-up visits were performed at 1 and 3 months
nd included clinical status, laboratory examinations, ECG,
chocardiography, safety, adverse events, and medications.
ll patients received aspirin, clopidogrel, angiotensin-
Abbreviations and Acronyms
EF  ejection fraction
FIRSTLINE-AMI  Front-Integrated Revascularization
and Stem Cell Liberation in
Evolving Acute Myocardial
Infarction by Granulocyte Colony-
Stimulating Factor Trial
G-CSF  granulocyte colony-stimulating
factor
ISR  in-stent restenosis
MACE  major adverse cardiovascular
events
MI  myocardial infarction
MRI  magnetic resonance imaging
PCI  percutaneous coronary
intervention
STEMI  ST-segment elevation myocardial
infarction
TLR  target lesion revascularizationonverting enzyme inhibitors, beta-blockers, and statins at aischarge. The use of clopidogrel was mandatory for 4
eeks after PCI, and a recommendation to the general
ractitioner/cardiologist was given by our institution regard-
ng continuation of clopidogrel for 3 to 6 months. After
ompletion of the 3-month follow-up visit, patients entered
n observational study in order to assess long-term safety
nd clinical outcome of treatment up to 1 year. To assess
ccurrence of ISR, coronary angiography was performed 6
onths after enrollment (Fig. 1).
The study was conducted according to the national and
nternational regulations and was approved by the universi-
y’s ethics committee. All patients gave their written in-
ormed consent.
tudy objectives. PRIMARY END POINTS. The primary end
oints were changes of global and regional cardiac function
sing MRI from baseline (1 week after PCI) to 3 months of
ollow-up. Global function was determined by left ventric-
lar ejection fraction (EF). Regional myocardial function
as assessed as segmental systolic wall thickening of the
nfarct area.
ECONDARY END POINTS. Secondary end points comprised
hanges of end-diastolic and end-systolic myocardial thick-
ess, end-diastolic volume, end-systolic volume, and infarct
olume using MRI from baseline (1 week after PCI) to 3
onths of follow-up. Furthermore, change of myocardial
erfusion parameters were assessed from baseline to 3
onths. Occurrence of major adverse cardiac events
MACE), such as death, repeat MI or acute coronary
yndromes, coronary artery bypass grafting, and reinterven-
ion, as well as spontaneously reported adverse events were
ollowed up to 1 year after PCI. Changes of blood count and
iver enzymes, number and characterization of mobilized
tem cells (CD34/c-kit, CD34/CD31, CD34/
D133), and changes of inflammatory parameters were
nalyzed.
The sample size was determined to assess efficacy of
-CSF with regard to improvement of segmental systolic
all thickening and left ventricular EF. Detection of a
ifference of 1 mm in systolic wall thickening, and 8% in left
entricular EF, respectively, with an 80% power and an 
rror of 5%, would require 36 patients (18 patients for each
reatment group). We adjusted the sample size for an
stimated 10% loss of follow-up, which resulted in 20
atients in each group and a total sample size of 40 patients.
aboratory analyses. Complete blood count was routinely
ssessed using automated laboratory cell counter. C-reactive
rotein analysis was performed using turbidometry. Cyto-
ine level of interleukin-6 was assessed using enzyme-linked
mmunoadsorbent assay. Liver enzymes measurement was
erformed in a standard automated analyzer.
low cytometry. Cytometric analysis was performed using
flow cytometer (FACScan, Becton Dickinson, Heidel-
erg, Germany). Each analysis included 100,000 events. For
mmunophenotyping, we used the monoclonal antibodies
gainst CD31, CD34, CD45, CD117 (c-kit), CD133,
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G-CSF in Myocardial Infarction October 17, 2006:1712–21XCR4 (Clone 12G5, R&D Systems, Minneapolis, Min-
esota), conjugated with fluorescein isothiocyanate, phyco-
rythrin, or phycoerythrin cyanine-5 (BD PharMingen/
oulter Immunotech, Hamburg, Germany).
RI. The MRI examinations were carried out on a
.5-T whole-body scanner (Magnetom Sonata, Siemens
edical Solutions, Erlangen, Germany) at 3 time points;
he first examination was performed 1 week after success-
ul PCI (baseline, 1 week after PCI) to avoid overesti-
ation of myocardial impairment resulting from stun-
ing (6). Follow-up MRI was performed at 1 and 3
onths. Cardiac functional imaging was based on a
egmented CINE TrueFISP pulse sequence using a
hared echo technique (temporal resolution: 42 ms, voxel
ize: in-plane resolution 1.3  1.5 mm2, slice thickness:
mm). Functional assessment was performed with a
tack of slices with 1-cm distance in a double oblique
hort-axis orientation (7). Regional systolic myocardial
hickening was assessed on a segmental base (16-
egement model) as absolute and relative values deter-
ined in areas of infarction, border zone, and remote
reas not affected by infarction. Myocardial segments that
ere related to the infarct artery and presented with loss
f function as well as demonstrated late enhancement
ere judged to be infarct segments. Border zone seg-
igure 1. Study design. F/U  follow-up; G-CSF  granulocyte colony-
oronary intervention; s.c.  subcutaneously; STEMI  ST-segment elevents were defined as the 2 segments adjacent to the dnfarct region located in the same slice; diastolic and
nd-systolic thickness were added and divided by 2.
emote segments were those related to a non-infarct
rtery, had preserved function, and did not show late
nhancement. The myocardial viability was assessed us-
ng inversion recovery T1w contrast-enhanced MRI us-
ng the late enhancement technique using gadobenate
imeglumine (Multihance, Altana, Konstanz, Germany, 0.1
mol/kg bodyweight), as previously described (8).
Myocardial perfusion was assessed using a T1-weighted
aturation recovery gradient echo sequence with prospective
CG triggering during the first path of contrast agent.
hree slices with a thickness of 10 mm were acquired in a
asal, mid-papillary, and apical position in a short-axis view
very heart beat while breath holding (field-of-view 340 
65 mm2, in-plane spatial resolution 2.7  2.1 mm).
yperemia was induced with a continuous intravenous
nfusion of 140 g/kg · min1 adenosine (Adenoscan,
anofi, Munich, Germany, bolus 0.05 mmol/kg gadobenate
imeglumine, flow rate 5 ml/s). For perfusion analysis, the
eft ventricular myocardium was divided into 6 equiangular
egments per slice, and signal intensity time curves were
btained. The upslope value of the line from the foot point
o the signal maximum was used for further calculations.
he myocardial perfusion reserve index was calculated by
lating factor; MRI  magnetic resonance imaging; PCI  percutaneous
myocardial infarction.ivision of the corrected upslope of the stress examination
b
t
t
p
r
s
S
S
i
u
p
U
t
S
R
T
(
p
[
r
t
T
c
T
r
P
s
o
s
S
l
s
(
r
c
s
p
v
d
S
s
D
M
t
p
m
s
w
d
G
i
a
d
c
1715JACC Vol. 48, No. 8, 2006 Engelmann et al.
October 17, 2006:1712–21 G-CSF in Myocardial Infarctiony the corresponding segment’s corrected upslope value of
he rest examination. Microvascular obstruction was iden-
ified as described previously (9). All MR analyses were
erformed in consensus by 3 independent experienced
adiologists (B.J.W., A.H., A.W.) (8) who were unaware of
tudy treatment, clinical, or laboratory data of study subjects.
tatistical analysis. Results are expressed in mean values
D, or median (range) as indicated. Parametrical tests
ncluded paired t testing; categoric variables were assessed
sing chi-square or Fisher exact test where appropriate. For
erfusion analysis, non-parametrical tests (Mann-Whitney
test, Wilcoxon test) were used. A level of p  0.05 was
aken to indicate statistical significance (SPSS release 13.0,
PSS Inc., Chicago, Illinois).
ESULTS
he baseline characteristics were comparable in both groups
Table 1). All patients suffered from a partial or complete
roximal occlusion (Thrombolysis In Myocardial Infarction
TIMI] flow grade 0/1) of at least 1 coronary artery
esulting in extensive MIs. Percutaneous coronary interven-
ion was successfully achieved in all patients resulting in
IMI flow grade 2/3. The time from PCI to onset of stem
ell mobilization or placebo treatment was comparable.
here was no significant difference between the groups
egarding cardiovascular risk factors, thrombolysis before
CI, or use of glycoprotein IIb/IIIa antagonists. We used
tent sizes from 2.5 mm to 3.5 mm. Mean stent diameters,
Table 1. Baseline Characteristics of the Study
Patients (n)
Male sex (%)
Age (yrs)
Cardiovascular risk factors
Hypertension (%)
Diabetes mellitus (%)
Smoking (%)
Hypercholesterolaemia (%)
Percutaneous coronary intervention
Infarct related artery (LAD/CX/RCA)
Peak creatinin kinase (U/l)
Angina to PCI, h (range)
Use of glycoprotein IIb/IIIa inhibitor (%)
Thrombolysis prior to PCI (%)
Onset of stem cell mobilization/placebo
treatment after PCI, h (range)
Time from PCI to baseline MRI (days)
Medication at 3-month follow-up
Aspirin (%)
Clopidogrel (%)
Beta-blocker (%)
ACE inhibitors (%)
Diuretics (%)
Values represent mean  SD.
ACE  angiotensin-converting enzyme; CX  circumfleleft anterior descending artery; MRI  magnetic resonance imaging
coronary artery.r number of implanted stents, were comparable (data not
hown).
tem cell mobilization and laboratory parameters. Granu-
ocyte colony-stimulating factor treatment resulted in a
ignificant mobilization of different stem cell populations
Table 2, Fig. 2). Granulocyte colony-stimulating factor
esulted in a transiently 4-fold increase of leukocytes when
ompared with placebo. The number of endothelial precur-
ors increased 23- to 29-fold after G-CSF but not after
lacebo treatment. Both groups presented moderately ele-
ated inflammatory parameters before treatment, which
ecreased during treatment (Table 2).
afety of G-CSF administration. Granulocyte colony-
timulating factor was well tolerated in most patients.
uring the application of either G-CSF or placebo, no
ACE were observed. In 2 patients, G-CSF was discon-
inued at day 3 because of occurrence of bone pain and
ericardial effusion, respectively. The patient presenting
oderate to severe bone pain during application of G-CSF
uffered from a common cold. Pericardial effusion after MI
as also documented in 1 case treated with placebo.
During the observational period, several MACE were
ocumented in both treatment groups. One patient of the
-CSF group presented with a recurrent MI resulting from
n-stent thrombosis 14 days after initial stent procedure,
lthough the patient actually had taken aspirin and clopi-
ogrel. Initially, this patient had received 3 stents with a
umulative length of approximately 45 mm. The occlusion
lation
Therapy Stratum
p Value-CSF Placebo
23 21
87 91 NS
0  11 57  11 NS
74 71 NS
22 24 NS
65 52 NS
57 43 NS
1/3/9 12/3/6 NS
5  1,803 3,021  2,302 NS
2  45 51  53 NS
6–160) (7–168)
65 43 NS
17 14 NS
1  24 39  28 NS
2–107) (13–135)
2  2.6 7.7  2.9 NS
95 100 NS
52 29 NS
100 100 NS
100 100 NS
42 29 NS
y; G-CSF  granulocyte colony-stimulating factor; LAD Popu
G
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; PCI  percutaneous coronary intervention; RCA  right
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G-CSF in Myocardial Infarction October 17, 2006:1712–21ould be successfully re-opened. One patient of the G-CSF
reatment group died 3 weeks after the 6-month angiogra-
hy; autopsy examination was refused by the relatives. Two
atients of the placebo group, but none of the G-CSF
roup, received coronary bypass grafts. Four of 19 patients
21%) from the G-CSF group had an ISR of the infarct-
elated artery and required target lesion revascularization
TLR). Six of 21 patients (29%, p  0.721 when compared
ith G-CSF group) from the placebo group presented with
SR, and subsequent TLR was performed (Table 3). Four
atients from the G-CSF group refused to undergo
ollow-up angiography. None of them suffered from recur-
ent angina in the long term. When compared with placebo,
either cumulative incidences of MACE nor occurrence of
estenosis differed significantly from the G-CSF group.
One patient of the G-CSF group presented stool abnor-
alities and malaise at 3 months of follow-up. We found a
olon carcinoma that was treated using chemotherapy. The
omparison of the observed serious adverse events demon-
trated no significant difference of clinical events in both
reatment groups (Table 3).
yocardial function and perfusion assessed byMRI. Base-
ine, 1-month, and 3-month follow-up MRI were per-
ormed 7.9  2.7 days, 41.0  17.2 days, and 108.6  23.4
ays after PCI, respectively. Magnetic resonance imaging of
7 patients who completed 3-month follow-up (G-CSF
roup: n  19, placebo: n  18) demonstrated that left
able 2. Changes of Laboratory Parameters Including Stem
ell Populations
G-CSF Placebo p Value
BC (g/l)
Baseline 11.2  4 9.2  2.4 0.038
Day 5 42.9  25.7* 7.7  2.3 0.001
4 weeks 6.8  1.9 6.4  2.0 NS
12 weeks 7.1  1.8 7.4  2.4 NS
D34/CD133 (cells/l)
Baseline 1.6  0.9 1.8  1.0 NS
Day 5 46.1  33† 2.2  1.4 0.001
D34/CD31 (cells/l)
Baseline 2.0  0.9 2.2  1.0 NS
Day 5 46.4  32.9‡ 2.2  1.4 0.001
D34/c-kit (cells/l)
Baseline 2.5  1.4 2.2  1.2 NS
Day 5 41.2  26.8§ 3.3  3.3 0.001
RP (mg/dl)
Baseline 5.8  6.4 8.4  8.4 NS
Day 5 4.1  2 2.5  3.3 0.062
4 weeks 0.5  0.2 0.6  0.1 NS
12 weeks 0.5  0.3 0.5  0.1 NS
L-6 (ng/ml)
Baseline 64  67 50  70 NS
Day 5 18  13 12  12 NS
4 weeks 5.2  2.3 4.9  2.9 NS
12 weeks 5.2  3.8 4.6  2.6 NS
alues represent mean  SD. *p  0.001 between baseline and day 5; †p  0.002
etween baseline and day 5; ‡p  0.003 between baseline and day 5; §p  0.008
etween baseline and day 5.
CRP  C-reactive protein; IL  interleukin; WBC  white blood count; other
bbreviations as in Table 1.entricular EF was comparable at baseline (1 week after pCI) in both groups. Ejection fraction improved by 6.2 
.0% from baseline to 3 months of follow-up in G-CSF-
reated patients and by 5.3  9.8% after placebo treatment
p  0.77) (Fig. 3, Table 4). Other global and regional
yocardial function parameters are shown in Table 4.
nfarct volumes were comparable and decreased significantly
rom baseline to 3 months of follow-up in the G-CSF
reatment group. The infarct volume in the placebo group
as reduced by trend. Microvascular obstruction was observed
n 33% (G-CSF) and 29% (placebo) of cases (p  1.0).
Granulocyte colony-stimulating factor resulted in a sig-
ificantly increased resting perfusion in the area of infarc-
ion at baseline, and at 1 month of follow-up (Table 5).
esting perfusion at 3 months was slightly increased in
-CSF-treated patients. Adenosine-induced hyperemia re-
ulted in a significant increase of perfusion in both G-CSF-
nd placebo-treated subjects in infarct as well as in remote
reas. The myocardial perfusion reserve index was slightly
ncreased in infarct and remote areas in placebo-treated
atients compared with the G-CSF group.
ISCUSSION
he present findings demonstrate, for the first time, safety
nd feasibility of G-CSF treatment in patients suffering
rom late revascularized STEMI in a prospective, random-
zed, placebo-controlled analysis. Granulocyte colony-
timulating factor was not superior to placebo regarding
mprovement of global as well as regional myocardial
unction. As a secondary finding, the trial demonstrates
ignificant increase of myocardial perfusion in the short
erm. Several stem-cell populations, which are considered to
mprove myocardial regeneration or neovascularization, are
ignificantly mobilized by G-CSF. This cytokine was gen-
rally well tolerated, with no significantly higher rate of ISR
r MACE when compared with placebo.
The novel therapeutic concept of stem-cell mobilization
sing G-CSF in MI was made uncertain by Kang et al. (5),
ho described ISR to be a major adverse event. In contrast
ith this report, the present study and 4 recent publications
f clinical trials report rare occurrences of ISR or TLR
3,4,10,11). In addition, intravascular ultrasound in humans
emonstrated no increased neointima formation in G-CSF-
reated subjects (12). The lower rate of ISR in our study
atients may be influenced by the time point of G-CSF
dministration after establishment of complete revascular-
zation. Complete stem-cell mobilization in the MAGIC
ell trial (effects of intracoronary infusion of peripheral
lood stem-cells mobilized with G-CSF on left ventricular
ystolic function and restenosis after coronary stenting in
I) was achieved 4 days before elective PCI of the
nfarct-related artery (5) at the time of highest leukocyte
ount, which may have resulted in proangiogenic and
roinflammatory processes within the culprit lesion. Hill et
l. (13) recently reported another clinical study of 16
atients suffering from reproducible myocardial ischemia in
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October 17, 2006:1712–21 G-CSF in Myocardial Infarctionhom coronary revascularization had not been performed
efore G-CSF administration. In this trial, 2 cases of MI
ere observed, and 1 patient died 17 days after G-CSF
reatment (13). In contrast with our trial and the more
ecent studies (12,14), Hill et al. (13) did not administer
lopidogrel or glycoprotein IIb/IIIa antagonists during
-CSF treatment.
However, we documented several adverse events in
-CSF-treated subjects. One patient, who suffered from
I owing to an in-stent thrombosis, had received 3 stents
ith a total length of 45 mm into the left anterior descend-
ng coronary artery followed by clopidogrel and tirofiban
uring the initial procedure. In-stent restenosis and throm-
osis are reported to be associated with an increased lesion
nd stent length (15). One patient of the G-CSF group died
weeks after the 6-month follow-up angiography, which
ad demonstrated a good stent result and a normal myo-
ardial function. Death may have resulted from sudden
igure 2. Flow cytometry analysis of mobilized stem cells at baseline and 5
tem cell populations from peripheral blood measured by flow cytome
D34/CD117 cells in placebo and G-CSF-treated patients before and
ith placebo at day 5. (B) The R4 population demonstrates increases of p
-CSF.ardiac death, although ventricular arrhythmias have never leen documented in his medical history. One case of colon
arcinoma was observed in a patient from the G-CSF group
fter 3 months. The occurrence of a formerly undiagnosed
ntestinal tumor may be coincidental, because human bone
arrow donors, who receive G-CSF, do not show signifi-
ant increase of malignancies (16). Granulocyte colony-
timulating factor was shown to have no effect on cancer cell
roliferation in mice but promoted tumor growth via
nhanced angiogenesis (17).
In the present study, left ventricular function improved
ignificantly in both treatment groups, but G-CSF was not
uperior to placebo. Most animal studies reported improved
emodynamic and myocardial function when G-CSF was
dministered before or after establishment of infarction
2,18). One mechanism of repair, by which G-CSF may
mprove cardiac function after MI, is considered to be the
obilization of bone marrow–derived stem cells homing
nto the damaged tissue area, where they induce neovascu-
after initiation of granulocyte colony-stimulating factor (G-CSF). CD34
) Quantitative measurements of CD34/CD31, CD34/133, and
y 5 of treatment. *p  0.001; **p  0.001; ***p  0.001 when compared
sor cells in a representative patient before and at day 5 of treatment withdays
try. (A
at daarization (18,19). Homing of the stem cells can be im-
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G-CSF in Myocardial Infarction October 17, 2006:1712–21roved by the chemokine stromal cell–derived factor 1
SDF-1), which is intrinsically produced by the myocar-
ium after MI. As recently shown, the intramyocardial
elivery of SDF-1 combined with G-CSF increases homing
f c-kit stem cells (20). On the other hand, direct
ntiapoptotic effects of G-CSF via activation of the Jak/Stat
athway may contribute to an improved survival of cardio-
yocytes preventing left ventricular remodeling after MI
21). Recently, the G-CSF receptor was shown to be
p-regulated shortly after MI, indicating a sensitization of
he heart to direct influences of this specific cytokine (22).
Table 3. Safety Characteristics of the Study Po
Major adverse cardiac events
Death
(Re) myocardial infarction
Acute coronary syndrome
Coronary artery bypass grafting
Target lesion revascularisation because of in-stent
restenosis*
De novo lesion requiring PCI*
Spontaneously reported adverse events
Bone/muscle pain
Pneumonia
Pericardial effusion
Local inflammation at arterial puncture site
Colon carcinoma
Sustained CRP elevation of unknown origin
Cumulative spontaneously reported adverse events
Values are n (%). *19 of 23 patients from the G-CSF group a
coronary angiography.
Abbreviations as in Tables 1 and 2.igure 3. Change of global ejection fraction assessed by magnetic resonance im
months of follow-up. G-CSF  granulocyte colony-stimulating factor; PCIThe application of G-CSF in humans after MI results in
more heterogeneous pattern of effects. The FIRSTLINE-
MI (Front-Integrated Revascularization and Stem Cell
iberation in Evolving Acute Myocardial Infarction by
ranulocyte Colony-Stimulating Factor) trial demonstrated
n a randomized and controlled, but not blinded, study a
eneficial effect of G-CSF on MI (4,14). Treatment of 25
atients with G-CSF first given 85  30 min after imme-
iately performed PCI resulted in a significant improvement
f EF of 8% at 12 months, while EF of non-placebo
ontrolled subjects decreased by 5%. Another study ob-
tion
Therapy Stratum
p Value
G-CSF
(n  23)
Placebo
(n  21)
1 (4) 0 NS
1 (4) 0 NS
0 0
0 2 (10) NS
4 (21)* 6 (29)* NS
4 (21)* 2 (10)* NS
1 (4) 0 NS
2 (9) 0 NS
1 (4) 1 (5) NS
1 (4) 0 NS
1 (4) 0 NS
0 1 (5) NS
7 (30) 3 (14) NS
of 21 patients from the placebo group underwent follow-uppula
nd 21aging from baseline (1 week after percutaneous coronary intervention) to
 percutaneous coronary intervention. Bold squares  mean  SD.
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October 17, 2006:1712–21 G-CSF in Myocardial Infarctionerved a tendency of improvement of EF and left ventricular
nd-diastolic volume in G-CSF-treated subjects (11). In
his study, patients with late presentation were not submit-
ed to primary PCI. Granulocyte colony-stimulating factor/
lacebo was initiated at a lower dose and more rapid than in
he present study. Recently, in a prospective, non-
andomized, open-label study (3), 14 patients were treated
ith G-CSF 48 h after PCI for 7  1 days. The EF
ncreased by 8% in the G-CSF group, compared with 3% in
he control group. In contrast with the present investigation,
hese studies may be biased either by the absence of
ouble-blind placebo treatment or the selection of control
ubjects from patients, who refused G-CSF treatment.
Table 4. Myocardial Function Parameters Asse
Ejection fraction
Baseline (1 week after PCI) (%)
3 months (%)
p value†
 ejection fraction (% points)
LVEDV
Baseline (1 week after PCI) (ml)
3 months (ml)
p value†
 LVEDV (ml)
LVESV
Baseline (1 week after PCI) (ml)
3 months (ml)
p value†
 LVESV (ml)
Stroke volume
Baseline (1 week after PCI) (ml)
3 months (ml)
p value†
 stroke volume (ml)
Systolic myocardial thickening of infarct area
Baseline (1 week after PCI) (mm)
3 months (mm)
p value†
 SMTinfarct area (mm)
Systolic myocardial thickening of infarct border zone
Baseline (1 week after PCI) (mm)
3 months (mm)
p value†
 SMTborderzone (mm)
Systolic myocardial thickening of remote area
Baseline (1 week after PCI) (mm)
3 months (mm)
p value†
 SMTremote area (mm)
Infarct volume
Baseline (1 week after PCI) (ml)
3 months (ml)
p value†
 infarct volume (ml)
Values represent mean  SD. *Between treatment groups
resonance imaging.
LVEDV  left ventricular end-diastolic volume; LVESV
thickening; other abbreviations as in Table 1.ore recently, a double-blind, randomized, placebo- Sontrolled trial investigated the use of G-CSF versus pla-
ebo after immediately performed PCI in patients suffering
rom acute MI (n  87) (10). The time point of G-CSF
nitiation in this trial was comparable to our study, but PCI
as performed earlier. The systolic wall thickening im-
roved by 17% in the infarct area of both G-CSF- and
lacebo-treated patients. Both groups demonstrated im-
rovement of EF by 8%, but G-CSF was not superior to
lacebo.
In contrast to the variety of recently published clinical
rials, the present study focused on the effects of G-CSF in
atients suffering from subacute MI who were admitted late
or PCI. The outcome of patients suffering from subacute
by Magnetic Resonance Imaging
Therapy Stratum
p Value*
G-CSF
(n  19)
Placebo
(n  18)
41  12 44  9 NS
47  12 49.5  12 NS
0.007 0.035
6.2  9.0 5.3  9.8 NS
140  44 149  32 NS
145  61 162  52 NS
NS NS
2  42 13  46 NS
83  38 87  21 NS
79  46 85  44 NS
NS NS
5  26 2  35 NS
57  21 63  20 NS
65  21 77  22 NS
NS 0.041
6  24 15  28 NS
2.7  2.3 3.1  2.5 NS
3.1  1.5 3.6  1.7 NS
NS NS
0.5  2.0 0.9  2.1 NS
2.9  1.6 3.0  1.9 NS
3.5  2.6 3.2  2.0 NS
NS NS
0.4  2.3 0.5  2.2 NS
6.0  1.8 6.6  3.1 NS
5.6  2.5 6.5  2.2 NS
NS NS
0.6  2.5 0.6  2.3 NS
30  11 35  20 NS
25  11 31  18 NS
0.015 0.08
5  6 5  11 NS
ween baseline (1 week) and 3-month follow-up magnetic
ventricular end-systolic volume; SMT  systolic myocardialssed
; †betTEMI is considered to be serious; patients are threatened
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G-CSF in Myocardial Infarction October 17, 2006:1712–21y progressive myocardial dysfunction resulting from the
ong time interval between onset of infarction to revascu-
arization (1). The initial EFs were markedly reduced in
oth study groups reflecting an extended myocardial dam-
ge in those patients. Most other trials included patients
resenting less severe myocardial dysfunction (4,23). Mi-
rovascular obstruction, which may have contributed to the
bserved myocardial dysfunction, occurred in both treat-
ent groups within a minority of patients in equal measure.
The time point of G-CSF initiation after successful PCI
ay be an important factor, because G-CSF treatment was
tarted very rapidly in the FIRSTLINE-AMI trial. In our
tudy, G-CSF and placebo treatment were initiated at an
verage of 31  24 h after successful revascularization. In a
arger trial of 114 subjects (G-CSF n  56) (23), patients
eceived G-CSF 5 days after immediately performed PCI.
he very late treatment resulted in a small decrease of
nfarct size in both groups (G-CSF 6.2  9.1% vs. 4.9
8.9% in placebo control subjects, p  0.56) and no
ubstantial increase of EF in both groups. This result
upports the hypothesis that late administration after PCI
ay diminish the potential benefit of G-CSF as demon-
Table 5. Myocardial Perfusion Assessed by Ma
G-
(n 
Perfusion at rest (Upslope) [signal intensity]
Infarct area
Baseline (1 week after PCI) 1.1 (0.
1 month 1.1 (0.
3 months 1.0 (0.
p value† N
Remote area
Baseline (1 week after PCI) 1.2 (0.
1 month 1.1 (0.
3 months 1.0 (0.
p value† N
Perfusion with adenosine stress (Upslope) [signal int
Infarct area
1 month 2.3 (0.
3 months 1.9 (0.
p value N
Remote area
1 month 2.8 (0.
3 months 1.9 (0.
p value N
MPRI (Upslopestress/Upsloperest)
Infarct area
1 month 1.5 (0.
3 months 1.7 (0.
p value N
Remote area
1 month 1.7 (0.
3 months 1.7 (0.
p value N
Values represent median (range). *Between treatment groups;
to Upslope at rest; §p  0.005 when compared to upslope a
MPRI  myocardial perfusion reserve index; other abbretrated in animal studies (21). 0In the current trial, we demonstrate an increased myo-
ardial perfusion at rest in G-CSF-treated patients within 1
onth. The reason for elevated perfusion assessed by
aseline MR may result from the late time point of
xamination. Baseline MR was performed an average of 8
ays after PCI. At that point, the 5-day course of G-CSF
as already administered, and early effects of G-CSF on
yocardial perfusion may have occurred. The beneficial
ffect of G-CSF on myocardial perfusion has not been
stablished in humans. However, increased cardiac blood
ow and metabolism after G-CSF treatment was shown in
baboon model of infarction (24). Mechanisms that pro-
ote enhanced myocardial perfusion include significant
elease of endothelial progenitor cells into circulation, as
bserved in our study. In addition, paracrine angiogenic
actors, such as vascular endothelial growth factor, are
eleased by neutrophils after administration of G-CSF and
ncrease neovascularization in ischemic tissue (19). En-
anced neovascularization may serve as one important
echanism facilitating reduction of infarct size after MI.
he reduction of infarct size was significant in the G-CSF
roup, but less so in the control group (p  0.15 vs. p 
ic Resonance Imaging
Therapy Stratum
p Value*
Placebo
(n  17)
) 0.7 (0.3–1.5) 0.048
) 0.7 (0.1–1.9) 0.016
) 0.8 (0.1–2.4) NS
NS
) 0.9 (0.2–2.2) NS
) 0.7 (0.2–1.6) NS
) 0.9 (0.1–1.9) NS
NS
]
)‡ 1.4 (0.3–3.4)§ NS
)‡ 1.5 (0.1–3.9)§ NS
NS
)‡ 1.6 (0.6–4.8)§ NS
)‡ 1.8 (0.1–3.6)§ NS
NS
) 2.3 (0.7–13) NS
) 2.0 (0.2–29) NS
NS
) 2.1 (0.8–7.3) NS
) 2.2 (0.1–32) NS
NS
een baseline and 1 month F/U; ‡p  0.005 when compared
s as in Table 1.gnet
CSF
17)
3–2.0
4–5.6
4–2.1
S
2–3.3
4–7.9
4–2.5
S
ensity
3–8.0
9–3.0
S
4–8.9
9–4.4
S
5–5.8
6–2.6
S
9–3.1
4–3.6
S
†betw.08). Interestingly, the absolute infarct size was smaller in
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October 17, 2006:1712–21 G-CSF in Myocardial Infarction-CSF-treated patients. We recently demonstrated in a
urine model of infarction that G-CSF results in a reduced
nfarct size and an enhanced arteriogenesis in the peri-
nfarct area mediated by an increased expression of the
ntracellular adhesion molecule-1 on endothelial cells (25).
In summary, G-CSF treatment appears to be safe in the
ajority of subjects suffering from MI, when successful PCI
as performed. The occurrence of 1 death and 1 MI in the
-CSF group necessitates a careful patient monitoring
uring further studies. Granulocyte colony-stimulating fac-
or was not superior to placebo regarding improvement of
yocardial function in patients with subacute infarctions in
hom delayed PCI was performed. Granulocyte colony-
timulating factor resulted in a significant increase of myo-
ardial perfusion within 1 month after PCI. Due to its phase
I character, the present study is limited by the relatively low
umber of patients. We conclude that further research
hould focus on immediate administration of G-CSF in
arly revascularized MI and on larger multicenter trials
nvestigating clinical outcome.
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